IVIVA Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

IVIVA Medical, a San Diego-based tissue engineering company founded in 2018 and now a United Therapeutics subsidiary, is pioneering the development of implantable bioartificial kidneys. The company's core technology platform utilizes advanced 3D printing to fabricate complex, layered vascular scaffolds that are seeded with cells to create functional renal tissue. This approach aims to provide a permanent, curative solution for ESRD patients, potentially eliminating the need for dialysis and overcoming the severe shortage of donor kidneys. The program is in the pre-clinical research and development stage, representing a high-risk, high-reward frontier in regenerative medicine.

NephrologyTransplantation

Technology Platform

Proprietary 3D bioprinting platform for creating layered, vascularized scaffolds from biologic materials, which are then populated with renal cells to form human-scale, functional solute-exchange grafts intended to replace kidney function.

Opportunities

The addressable market is enormous, encompassing hundreds of thousands of dialysis-dependent patients globally who have no viable transplant option.

A successful bioartificial kidney would command premium pricing as a one-time curative therapy, displacing the high recurring costs of dialysis and creating a multi-billion dollar product category.

It would also establish a foundational platform technology potentially applicable to other complex organs.

Risk Factors

The scientific and engineering challenges of creating a functional, implantable organ are unprecedented, with high risk of technical failure.

Regulatory pathways for such a novel product are undefined and could be prohibitively lengthy or stringent.

Manufacturing a living, complex 3D tissue at scale with consistency presents a monumental commercialization hurdle.

Competitive Landscape

Competition includes companies advancing portable/wearable dialysis devices (e.g., AWAK, Outset Medical) and those in the xenotransplantation space (e.g., United Therapeutics' own Revivicor unit, eGenesis). Traditional dialysis providers (Fresenius, DaVita) represent the incumbent standard of care. IVIVA's approach is distinct in aiming for a fully implantable, biological organ replacement, placing it in a nascent and highly specialized competitive segment.

More companies in Regenerative Medicine →More companies in United States →